Week In Review: Another Billion Dollar Week For China Life Science Deals

Published: Oct 02, 2017

September 30, 2017

Deals and Financings

• Shanghai Pharma may acquire part of Alvogen, a US-based global generic company worth $4 billion, and the part might be Alvogen's US operations;
• Shandong Weigao Group, a medical device company, will acquire Argon Medical Devices of Texas for $850 million;
• Simcere Pharma of Nanjing partnered with Amgen to co-develop and commercialize four Amgen biosimilars in China;
• China's Ping An Insurance paid $245 million to acquire a 10% stake in Japan's Tsumura, which makes China and Japanese herbal drugs;
• China Resources Gosun Pharma in-licensed greater China rights to a novel antibiotic from Switzerland's Basilea in a $152 million deal;
• Shenzhen Salubris Pharma made a $5 million investment in GO Therapeutics, a Cambridge, MA pre-clinical oncology company;
• Hangzhou Chengyuan Genomics, an R&D tools startup, will market a single cell RNA sequencing device in China for Boston's 1CellBiO.

Trials and Approvals

• Gilead Sciences (NSDQ: GILD) of the US received CFDA approval for Sovaldi®, its once-daily oral treatment for chronic hepatitis C with ribavirin and/or interferon;
• Novo Nordisk won CFDA approval for China use of its latest diabetes drug, Tresiba;
• MicroPort Scientific and LivaNova were approved to market their RegaTM family of pacemakers in China;
• Sinovac Biotech of Beijing reported positive topline results from a Phase III trial of its chickenpox vaccine;
• Shanghai's Zai Lab dosed the first patient in a China Phase III trial of its lead drug, a PARP inhibitor.

Back to news